Clinical trial

De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

NCT04675827

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-01-17

PhasePHASE2

Study timeline

Study start (actual)2022-01-17Date precision: day

Registry last updated2024-12-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Breast Cancerunresolved

ER-Negative Breast Cancerunresolved

PR-Negative Breast Cancerunresolved

Node-negative Breast Cancerunresolved

Interventions

Pertuzumab and tratuzumab fixed dose combinationDRUG

Trastuzumab emtansineDRUG

Sponsors & collaborators

Jules Bordet Institutelead sponsor

Breast International Groupcollaborator

Hoffmann-La Rochecollaborator

International Drug Development Institutecollaborator

Institut Curiecollaborator

Mapped research locations

SeoulSouth Korea7 ParisFrance3 BrusselsBelgium2 BordeauxFrance2 IncheonSouth Korea2 ToulouseFrance1 MarseilleFrance1 MontpellierFrance1 LyonFrance1 StrasbourgFrance1 LilleFrance1 NantesFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04675827 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.